Clinical trials
Active, not recruiting Lymphoma, T-Cell, Cutaneous trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 15 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| City of Hope Medical Center | 2 |
| M.D. Anderson Cancer Center | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Bio-Path Holdings, Inc. | 1 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | 1 |
| Daiichi Sankyo Co., Ltd. | 1 |
| Ossium Health, Inc. | 1 |
| Treeline Biosciences, Inc. | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, T-Cell, Cutaneous | 15 |
| Mycosis Fungoides | 9 |
| Lymphoma | 7 |
| Lymphoma, Follicular | 6 |
| Sezary Syndrome | 6 |
| Hodgkin Disease | 5 |
| Lymphoma, Large-Cell, Anaplastic | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Immunoblastic Lymphadenopathy | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
Trials
Showing 76 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.